Article ID Journal Published Year Pages File Type
8454732 Lung Cancer 2016 24 Pages PDF
Abstract
These results suggest that EGFR TKI therapy is effective in patients with L861Q/G719X/Del-19 + L858R/Del-19 or L858R + other mutations; less effective in patients with 20ins/Del-19 or L858R + T790 M.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Authors
, , , , , , , , , , ,